We report four cases of late avascular necrosis (AVN) of the proximal part of the scaphoid following apparent healing of acute scaphoid fractures. One patient had been treated conservatively, by plaster immobilization, and the other three had undergone internal fixation of their acute fractures. The onset of symptoms associated with AVN varied, being as late as 2 years in one patient. Late AVN following healing of a scaphoid fracture does not appear to have been previously recognized, perhaps due to the fact that patients are seldom followed up for long enough. We feel that this condition is in many ways analogous to late AVN following femoral neck fractures and as such is a special complication related to the fact that both bones are intracapsular and have a precarious blood supply.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0266-7681(05)80174-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proximal humerus fracture dislocations: outcomes of management.
ANZ J Surg
January 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Purpose: Proximal humerus fracture dislocations are amongst the most severe proximal humerus injuries, presenting a challenging management problem. The aim of this study was to report on long-term outcomes of management of proximal humerus fracture dislocations.
Methods: Patients with a proximal humerus fracture dislocation managed at a Level 1 trauma centre from January 2010 to December 2018 were included.
Avascular necrosis in pediatric rheumatic diseases: an Italian retrospective multicentre study.
Ital J Pediatr
January 2025
Pediatric Immuno-Rheumatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Background: Atraumatic avascular necrosis (AVN) is a severe condition that may complicate the course of rheumatic diseases and contribute to long-term damage. However, there is a lack of evidence on this rare event in pediatric rheumatology. The aim of our study was to evaluate the occurrence of avascular necrosis in the context of rheumatologic diseases in Italy and to describe the main demographic and clinical features of AVN patients, with a particular focus on treatment background.
View Article and Find Full Text PDFBeta-adrenergic receptor antagonist propranolol prevents bisphosphonate-related osteonecrosis of the jaw by promoting osteogenesis.
J Dent Sci
January 2025
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Background/purpose: Bisphosphonate-related osteonecrosis of the jaw (BRONJ), a complication arising from the use of bisphosphonates (BPs), inflicts long-term suffering on patients. Currently, there is still a lack of effective treatments. This study aimed to explore the preventive effects of propranolol (PRO) on BRONJ in vitro and in vivo, given PRO's potential in bone health enhancement.
View Article and Find Full Text PDFMedialization of shaft of humerus to provide medial buttress and prevent varus collapse in 3- and 4-part proximal humerus fractures: review of the surgical technique.
JSES Rev Rep Tech
February 2025
Department of Orthopaedics, Krishna Institute of Medical Sciences, Secunderabad, Telanagana, India.
Hypothesis: Proximal humerus fractures present a treatment challenge due to varied fracture configurations and a lack of consensus on optimal management. Locking plate designs offer promising solutions, yet technical guidelines for successful outcomes remain elusive. Complications are common, with fixation-related failures often attributed to varus collapse.
View Article and Find Full Text PDFMedication-related osteonecrosis of the jaw in patients with cancer using zoledronic acid and denosumab: Single-center retrospective study.
J Oncol Pharm Pract
January 2025
Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but potentially severe condition that significantly affects the quality of life of patients with cancer. This study evaluated MRONJ in patients with cancer treated with zoledronic acid (ZOA) and denosumab (Dmab).
Methods: The survey investigated patients who were diagnosed with MRONJ at the Department of Oral and Maxillofacial Surgery after receiving either ZOA or Dmab at the Saitama Medical Center, Saitama Medical University, between April 1, 2022, and March 31, 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!